JP Morgan Chase
NVLN

JP Morgan Chase’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

JP Morgan Chase’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-600
Closed – – 6102
2019
Q3 		$0 Hold
600
– – ﹤0.01% 6104
2019
Q2 		$0 Sell
600
-1,364
-69% -$1.52K ﹤0.01% 6154
2019
Q1 		$3K Buy
1,964
+1,364
+227% +$1.55K ﹤0.01% 5666
2018
Q4 		$1K Hold
600
– – ﹤0.01% 5650
2018
Q3 		$2K Hold
600
– – ﹤0.01% 5629
2018
Q2 		$2K Sell
600
-3,045
-84% -$12.2K ﹤0.01% 5476
2018
Q1 		$13K Sell
3,645
-228
-6% -$967 ﹤0.01% 5144
2017
Q4 		$12K Sell
3,873
-3,867
-50% -$18.6K ﹤0.01% 5243
2017
Q3 		$54K Buy
7,740
+6,336
+451% +$50.8K ﹤0.01% 4455
2017
Q2 		$13K Sell
1,404
-8,888
-86% -$85.6K ﹤0.01% 4621
2017
Q1 		$110K Buy
10,292
+6,440
+167% +$65.8K ﹤0.01% 4295
2016
Q4 		$32K Buy
+3,852
New +$34.1K ﹤0.01% 4619

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

JP Morgan Chase's NVLN Position: Q4 2019 in Review

JP Morgan Chase sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 600 shares.

JP Morgan Chase first reported a position in NVLN in Q4 2016 and held it in 12 quarters. The position peaked at $110K in Q1 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • JP Morgan Chase reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • JP Morgan Chase sold 600 Novelion Therapeutics Inc. Common Shares shares in Q4 2019.
  • JP Morgan Chase first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 12 quarters.
  • JP Morgan Chase's Novelion Therapeutics Inc. Common Shares position peaked at $110K in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.